Compare Biogen Inc (BIIB) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Firy Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Firy Inc. trades at $9.98 (market cap $159.51M). The key difference: Biogen Inc is far larger — about 188.9× Firy Inc.'s market cap. Which is the better fit depends on your goals.
| BIIB | FIRY | |
|---|---|---|
Market Cap | $30.13B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $12.45 |
52-Week Low | $128.93 | $2.28 |
Enterprise Value | $37.20B | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
FIRY (formerly Skillz Inc.) trades at $9.98, down 4.77% today, with a bullish technical signal from moving averages. The company shows persistent losses with a -67.38% net margin in 2025 despite an 87.75% gross margin, while revenue declined from $270M in 2022 to $104M in 2025. Recent developments include a legal victory securing $719M and a corporate rebranding to FIRY.
The outlook remains challenging due to sustained negative cash flows and profitability issues, though the legal win provides a potential catalyst. Analyst sentiment is mixed with 60% hold ratings. Key risks include execution on profitability and competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
